Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 345

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study

Gane, Edward, Verdon, Daniel J., Brooks, Anna E., Gaggar, Anuj, Nguyen, Anh Hoa, Subramanian, G. Mani, Schwabe, Christian, Dunbar, P. Rod·2019·Journal of Hepatology

Abstract

BACKGROUND AND AIMS To evaluate the hypothesis that increasing T-cell frequency and activity may provide durable control of hepatitis B virus (HBV), we administered nivolumab, a PD-1 inhibitor, with or without GS-4774, an HBV therapeutic vaccine, in virally-suppressed patients with HBeAg negative chronic HBV. METHODS In a Phase 1b study, patients received either single dose of nivolumab at 0.1 mg/kg (n=2) or 0.3 mg/kg (n=12), or 40 yeast units of GS-4774 at baseline and Week 4 and 0.3 mg/kg of nivolumab at Week 4 (n=10). The primary efficacy endpoint was mean change in HBsAg 12 weeks after nivolumab. Safety and immunologic changes were assessed through Week 24. RESULTS There were no grade 3 or 4 adverse events or serious adverse events. All assessed patients retained T-cell PD-1 receptor occupancy 6-12 weeks post-infusion, with a mean total across 0.1 and 0.3 mg/kg cohorts of 76% (95% CI 75,77), and no significant differences were observed between cohorts (p=0.839). Patients receiving 0.3 mg/kg nivolumab without and with GS-4774 had mean declines of -0.30 (95% CI, -0.46,-0.14) and -0.16 (95% CI, -0.33,0.01) log10 IU/mL, respectively. Patients showed significant HBsAg declines from baseline (p=0.035) with three patients experiencing declines of >0.5 log10 by end of study. One patient, whose HBsAg went from baseline 1173 IU/mL to undetectable at Week 20, experienced an ALT flare (grade 3) at Week 4 that resolved by Week 8 accompanied by a significant increase in peripheral HBsAg-specific T-cells at Week 24. CONCLUSIONS In virally suppressed HBeAg-negative patients, checkpoint blockade was well-tolerated and led to HBsAg decline in most patients and sustained HBsAg loss in one patient. Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au/) number: ACTRN12615001133527.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2019.06.028

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 345

Metadata

Authors
Gane, E., Verdon, D. J., Brooks, A. E., Gaggar, A., Nguyen, A. H., Subramanian, G. M., Schwabe, C., & Dunbar, P. R.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2019-11
Volume
71
Issue
5
Pages
900-907
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2962219096
Cited by
345
References
26
FWCI
27.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. https://app.cochat.ai/papers/10.1016/j.jhep.2019.06.028
The paper
Gane, E., Verdon, D. J., Brooks, A. E., Gaggar, A., Nguyen, A. H., Subramanian, G. M., Schwabe, C., & Dunbar, P. R. (2019). Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2019.06.028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.